Weight Control at WeightControl.com

Henry Ford Study Finds Less Alcohol Intake in Patients on Obesity Medications

Lisa Miller-Matero, PhD
Associate Scientist & Associate Director of Health Services Research
Henry Ford Health

What was exciting was that those who were drinking at higher or even what is considered hazardous levels had a greater likelihood of reducing alcohol use.

WeightControl.com: What is the background for this study?

Response: We partnered with colleagues at Weight Watchers (WW International) on this project after they began receiving reports from their members that they noticed reduced desire for alcohol use. Though there has been some research conducted in animal studies, research in humans has been lacking, especially examining changes in alcohol use.

Ohio State University Studies Changes in Food Waste Among New Weight Loss Drug Users

When an increasingly large segment of consumers is buying less food and perhaps wasting less food, it can reverberate through the food system

WeightControl.com Interview with:
Brian E. Roe, Ph.D.
Associate Chair
Fred N. VanBuren Professor of Farm Management
The Ohio State University

WeightControl.com: What is the background for this study?

Response: The use of anti-obesity medications (AOMs) is on the rise in the United States with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists to the pharmaceutical market. It is estimated that 6% of the U.S. adult population is on a GLP-1 medication while as many as 12% have been on one at some point. While it is well-documented that people eat less food when on the drug, little is known about its impact on how much food consumers waste, which is critical because about a third of food purchased is never consumed.

Obesity Drugs: More Protein Needed to Offset Muscle Loss

Multiple studies now report that the amounts of skeletal muscle loss with these new powerful weight loss agents is quite large, up to 40% of weight loss.

WeightControl.com Interview with:

Steven B. Heymsfield, M.D.
Professor and Director of the Body Composition-Metabolism Laboratory
Pennington Biomedical Research Center of the
Louisiana State University System in Baton Rouge

WeightControl.com: What is the background for this study?

Response: The recent introduction of glucagon receptor-1 agonists for weight control opens a new era in obesity pharmacotherapy. The greater weight loss with the new drugs is revealing a long-standing recognition that negative energy balance is accompanied by not only decrements in body fat, but also lean protein-containing tissues such as liver, kidney, and skeletal muscle.

More than Just for Diabetes: SGLT2 Inhibitors Benefit Patients with Heart Failure

SGLT2 inhibitors, from being merely an antidiabetic drug, are contributing a lot to the global fight against cardiovascular and renal diseases.

WeightControl.com Interview with:
Bernardo Cortese, MD FESC FSCAI
Interventional Cardiologist
President, Scientific Committee Fondazione Ricerca e Innovazione Cardiovascolare,
CEO, DCB Academy
www.fondazioneric.org
www.bernardocortese.com

WeightControl.com: What is the background for this study? What are the main findings?

Response: Our report seeks to elucidate the current role of SGLT2 inhibitors in the management of cardiovascular disease and the comprehensive spectrum of heart failure, namely when the heart start deteriorating in its functions.

We start focusing on the pharmacological properties of this class of drugs, thereafter we go through a synthesis and analysis of data derived from the main clinical trials which have involved this class when applied to the cardiovascular patient. Specifically, we aim to consolidate findings that substantiate the safety profile of SGLT2 inhibitors concerning cardiac, renal, and metabolic parameters. Furthermore, our study explores the therapeutic impact of these agents in the context of managing and treating type 2 diabetes.

These “glucoscape maestros”, initially prescribed to diabetic patients, showed a great safety and benefit profile in patients with renal impairment and, most importantly, with a failing heart.

Pages: 12